e-learning
resources
London 2016
Sunday, 04.09.2016
Features and impact of comorbidities in COPD
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Morphological markers of resistance bronchial mucosa of smokers to the development of COPD
Ivan Kremis (Tomsk, Russian Federation), Ivan Kremis, Ekaterina Bukreeva, Elena Gereng
Source:
International Congress 2016 – Features and impact of comorbidities in COPD
Session:
Features and impact of comorbidities in COPD
Session type:
Thematic Poster
Number:
650
Disease area:
Airway diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
Ivan Kremis (Tomsk, Russian Federation), Ivan Kremis, Ekaterina Bukreeva, Elena Gereng. Morphological markers of resistance bronchial mucosa of smokers to the development of COPD. Eur Respir J 2016; 48: Suppl. 60, 650
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Panel discussion on Basic translational and clinical research – building a career in paediatric pulmonology- experiences from clinicians in lower middle income countries
Panel discussion on ERS Statement – A core outcome set for clinical trials evaluating the management of COPD exacerbations
ERS statement: a core outcome set for clinical trials evaluating the management of COPD exacerbations
Related content which might interest you:
Features of the bronchial mucosa in heavy smokers with and without chronic obstructive pulmonary disease
Source: International Congress 2015 – COPD: interesting notes
Year: 2015
Airway epithelial cell apoptosis and inflammation in COPD, smokers and nonsmokers
Source: Eur Respir J 2013; 41: 1058-1067
Year: 2013
Myofibroblast expression in airways and alveoli is affected by smoking and COPD
Source: Annual Congress 2013 –COPD: new markers of diseases
Year: 2013
Cigarette smoke alters the EZH2/DAB2IP expression in bronchial epithelial cells. A risk factor for lung cancer in COPD patients
Source: International Congress 2016 – Studies in airway cell biology
Year: 2016
Alterations of the soluble proteome of airway epithelial cells in COPD
Source: Annual Congress 2013 –New strategies in epigenomic research to study lung diseases (DNA rearrangements, RNA, methylation, proteosome)
Year: 2013
Small airway function in smokers without airway obstruction
Source: International Congress 2015 – Exploring mechanisms in obstructive airway diseases
Year: 2015
Role of chronic exposure to cigarette smoke on endoglin/CD105 expression in airway epithelium
Source: International Congress 2015 – Cellular and molecular mechanisms of COPD and emphysema
Year: 2015
Airway mucosal inflammation in COPD is similar in smokers and ex-smokers: a pooled analysis
Source: Eur Respir J 2007; 30: 467-471
Year: 2007
Effect of 1-year smoking cessation on airway inflammation in COPD and asymptomatic smokers
Source: Eur Respir J 2005; 26: 835-845
Year: 2005
Nasal and bronchial inflammation markers in smokers before and after smoking cessation program
Source: Annual Congress 2005 - Smoking cessation in respiratory diseases: methods and results
Year: 2005
Reduced airway expression of cytoprotective CC10 in COPD patients and mice exposed to cigarette smoke
Source: Annual Congress 2013 –COPD: experimental biology
Year: 2013
The effect of smoking on the activity of inflammatory markers in patients with COPD
Source: Annual Congress 2013 –Tobacco use in different countries: crisis to disease
Year: 2013
IL-17A is elevated in patients with COPD and contributes to airway remodeling by acting on fibroblasts
Source: International Congress 2016 – What's new in biomarker analysis?
Year: 2016
Expression of MIC-A in bronchial epithelium associates with cigarette smoking: a sign of induced autoimmune mechanisms?
Source: Annual Congress 2005 - Lung structure: current concepts
Year: 2005
Risk factors of bronchial hyperresponsiveness in COPD
Source: International Congress 2015 – COPD: interesting notes
Year: 2015
Autoreactivity and inflammatory phenotypes in patients with COPD and bronchial asthma
Source: International Congress 2016 – Laboratory tests and cell biology in allergy and immunology
Year: 2016
Prevalence of small airway dysfunction among GOLD stages in COPD patients
Source: International Congress 2016 – Functional assessment of the airways
Year: 2016
Effect of whole cigarette smoke exposure and CCSP on MUC5AC mucin production in primary cultures of human bronchial epithelial cells at air-liquid interface of COPD, smokers and control patients
Source: International Congress 2015 – Translational studies in airway cell biology
Year: 2015
Identification of oxidative stress markers and their association with inflammation in smokers and early chronic obstructive pulmonary disease (COPD)
Source: International Congress 2016 – Hospitalisation and comorbidities in chronic lung diseases
Year: 2016
Cellular composition of bronchial brush-biopsies in dependence on smoking and etiology of COPD exacerbation
Source: Eur Respir J 2007; 30: Suppl. 51, 403s
Year: 2007
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept